# Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes

> **NCT04854083** · PHASE4 · UNKNOWN · sponsor: **Kirsi Pietiläinen** · enrollment: 50 (estimated)

## Conditions studied

- Type2 Diabetes

## Interventions

- **DRUG:** Semaglutide, 1.34 mg/mL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04854083
- **Lead sponsor:** Kirsi Pietiläinen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-17
- **Primary completion:** 2025-08
- **Final completion:** 2025-08
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-03-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04854083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04854083, "Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04854083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*